ライフサイエンスコーパス: thrombolytic agent

1 therapy and it is also used clinically as a thrombolytic agent.

2 sue plasminogen activator, is an alternative thrombolytic agent.

3 ffinity obviates continuous infusion of this thrombolytic agent.

4 cing infarct size in patients treated with a thrombolytic agent.

5 py for acute ischemic stroke is the use of a thrombolytic agent.

6 in ischemia, independent of its effect as a thrombolytic agent.

7 PA) is a highly fibrin-specific single-bolus thrombolytic agent.

8 swered questions remain regarding the use of thrombolytic agents.

9 inogen activator are the currently available thrombolytic agents.

10 nimizes the duration of systemic exposure to thrombolytic agents.

11 tra-arterial thrombolysis, and trials of new thrombolytic agents.

12 d antiplatelet therapies in combination with thrombolytic agents.

13 congestive heart failure, who first received thrombolytic agents.

14 tients with myocardial infarction (MI) given thrombolytic agents.

15 be observed in 10 minutes without exogenous thrombolytic agents.

16 hic potential complication of treatment with thrombolytic agents.

17 te the utility of this assay as a screen for thrombolytic agents, a 14-amino-acid PAI-1-inhibitory pe

18 myocardial infarction treated initially with thrombolytic agents-a clinical application previously un

19 medications, including medications (such as thrombolytic agents and beta-blockers) that are associat

20 The use of thrombolytic agents and captopril had no significant eff

21 The use of thrombolytic agents and invasive treatment plans decline

22 , including intra-arterial administration of thrombolytic agents and mechanical interventions, show p

23 outcomes of patients with OTPHV treated with thrombolytic agents and with surgery since 1996.

24 F or both), time of VT/VF occurrence, use of thrombolytic agents, and eventual outcome are unclear.

25 New devices, new thrombolytic agents, and new antithrombotic agents are c

26 rlier treatment, the use of third-generation thrombolytic agents, and the use of primary angioplasty.

27 enting; more potent and more fibrin-specific thrombolytic agents; and new antithrombotic and antiplat

28 clinical trials have investigated the use of thrombolytic agents, anticoagulants, antiplatelet drugs

29 Tissue plasminogen activator is the only thrombolytic agent approved in the United States for tre

30 Thrombolytic agents, aspirin, beta-blockers, and angiote

31 learest indication for the administration of thrombolytic agents, but patients with acute pulmonary e

32 In the absence of any thrombolytic agent, clots fully retracted within 2.5 h a

33 % of patients aged 75 to 84 years received a thrombolytic agent compared with 21.4% between 1 June 19

34 atients younger than age 55 years received a thrombolytic agent during hospitalization for acute myoc

35 ctive treatment option in conjunction with a thrombolytic agent for stroke patients.

36 and IPF2alpha-I levels in patients receiving thrombolytic agents for acute MI.

37 y be justified in severe cases, the role for thrombolytic agents for less symptomatic deep venous thr

38 TAFIa could enhance the efficacy of existing thrombolytic agents for the treatment of acute myocardia

39 ome after myocardial infarction treated with thrombolytic agents from a large international cohort.

40 nting, glycoprotein IIb/IIIa inhibitors plus thrombolytic agents, glycoprotein IIb/IIIa inhibitors pl

41 al, an appropriate dose of this single-bolus thrombolytic agent has been identified for phase III tes

42 te ST segment elevation MI, new single-bolus thrombolytic agents have been unable to break the "throm

43 Although current thrombolytic agents have proven their clinical benefit,

44 uture directions for a safer use of tPA as a thrombolytic agent in the setting of acute ischemic stro

45 Patients meeting ECG criteria were given thrombolytic agents in 49% of cases, but age, comorbidit

46 must be excluded prior to administration of thrombolytic agents in acute stroke.

47 All thrombolytic agents in current clinical usage are plasmi

48 as well as local intra-arterial delivery of thrombolytic agents in patients with acute stroke, are t

49 helped avoid the risks from angiography and thrombolytic agents in some or spurred the judicious use

50 ubbles not only enhance the effectiveness of thrombolytic agents in the presence of ultrasound but ma

51 py may be a non-invasive safe alternative to thrombolytic agents in treating thrombotic CVC occlusion

52 nergistic effect on thrombus disruption with thrombolytic agents in vitro.

53 Further study of this new thrombolytic agent is ongoing.

54 Streptokinase (SK), a widely used thrombolytic agent, is an efficient activator of human P

55 TNK-tPA, a fibrin specific second generation thrombolytic agent, is effective in reducing ischemic vo

56 Newer thrombolytic agents may have advantages, but are less we

57 Our findings indicate that thrombolytic agents may have therapeutic value in the tr

58 The effect of a thrombolytic agent on biochemical bond degradation was m

59 theterization was performed more often after thrombolytic agents (OR 1.85, 95% CI 0.97 to 3.54), but

60 s older age and therapy with anticoagulants, thrombolytic agents, or captopril affect long-term rates

61 minogen activator (TPA) with a direct-acting thrombolytic agent, plasmin, in an animal model of fibri

62 The use of thrombolytic agents (plasminogen activators) in the earl

63 VWF) that blocks VWF binding to GPIb, of the thrombolytic agent recombinant tissue plasminogen activa

64 Finally, we show that the thrombolytic agent streptokinase has therapeutic value f

65 f important virulence factors, including the thrombolytic agent streptokinase, the protease inhibitor

66 ich regulates the expression of pili and the thrombolytic agent streptokinase.

67 urokinase-type plasminogen activator or the thrombolytic agent streptokinase.

68 as in clots that have been treated with the thrombolytic agents streptokinase and alteplase.

69 lacing of the thrombus with a fibrin-binding thrombolytic agent such as alteplase is an alternative t

70 parin, oral anticoagulants, antibiotics, and thrombolytic agents such as urokinase and tissue plasmin

71 yocardial infarction less commonly receive a thrombolytic agent, use of thrombolytic therapy in this

72 oup analyses to assess the effect of type of thrombolytic agent used and the strategy of emergent hos

73 up, and were independent of both the type of thrombolytic agent used, and whether or not the patient

74 association between age and treatment with a thrombolytic agent was determined by crude and multivari

75 Use of a thrombolytic agent was inversely related to patient age:

76 However, the interaction with thrombolytic agents was not specifically assessed.

77 ocardial infarction, the odds of receiving a thrombolytic agent were significantly reduced for patien

78 ngiotensin-converting enzyme inhibitors, and thrombolytic agents were used in 72%, 39%, 32%, and 15%

79 olysis, but the relative benefits of various thrombolytic agents with earlier administration are unce

80 Over the past two decades, new thrombolytic agents with sufficient pharmacologic potenc